Type your tag names separated by a space and hit enter

Specific Considerations with Endocrine Disease - Pituitary Disease

Specific Considerations with Endocrine Disease - Pituitary Disease is a topic covered in the Clinical Anesthesia Procedures.

To view the entire topic, please or purchase a subscription.

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Explore these free sample topics:

Anesthesia Central

-- The first section of this topic is shown below --

Anterior Pituitary Gland

Anterior Pituitary Gland

  1. Physiology. The anterior pituitary regulates the thyroid and adrenal glands, the ovaries and testes, growth, and lactation by producing TSH, ACTH, follicle-stimulating hormone, luteinizing hormone, GH, and prolactin. A negative feedback system mediated by peripheral hormones tightly controls anterior pituitary secretion. Anterior pituitary adenomas may lead to hormone excess or hypopituitarism. Macroadenomas (>1 cm in diameter) can compress adjacent structures producing visual disturbances, seizures, or increased intracranial pressure (ICP).
  2. Anterior pituitary hyperfunction. Pituitary adenoma is the most common cause of anterior pituitary hyperfunction. Prolactinomas generally do not affect anesthetic management. The hyperthyroidism of a TSH-secreting adenoma and the hyperadrenalism of an ACTH-secreting adenoma are treated as described above. The anatomic and physiologic changes seen with GH-secreting tumors warrant careful consideration.
    1. Acromegaly (excess GH)
      1. Clinical features. GH stimulates bone, cartilage, and soft tissue growth leading to prognathism, subglottic narrowing of the trachea, and soft tissue overgrowth of the lips, tongue, epiglottis, and vocal cords. Connective tissue overgrowth can cause recurrent laryngeal nerve paralysis, carpal tunnel syndrome, and other peripheral neuropathies. These patients often develop glucose intolerance, muscle weakness, arthritis, osteoporosis, HTN, obstructive sleep apnea (OSA), congestive heart failure, and arrhythmias. They also have an increased incidence of coronary artery disease and colon carcinoma. The primary treatment is surgical removal of the tumor. Medical management for persistent disease after surgery includes dopamine agonists (bromocriptine and cabergoline), somatostatin analogs (octreotide and lanreotide), GH receptor antagonists (pegvisomant) and radiation therapy. Excision of GH-secreting pituitary adenomas is often performed transsphenoidally (see Chapter 25).
      2. Anesthetic considerations. Patients should be evaluated for other endocrinopathies and cardiac disease preoperatively. Conventional mask airways are often difficult to achieve, and endotracheal intubation can be challenging. Advanced airway and tracheostomy equipment should be available, and awake fiberoptic intubation should be considered. Small-diameter endotracheal tubes may be required. Serum glucose levels should be carefully monitored and muscle relaxants titrated using a peripheral nerve stimulator. Patients may be osteoporotic and have increased susceptibility to peripheral neuropathies. Careful positioning is necessary. Patients with OSA are at high risk for postoperative obstruction.
  3. Anterior pituitary hypofunction
    1. Etiologies. Pituitary adenoma is the most common cause of anterior pituitary hypofunction. Other causes of pituitary failure include trauma, radiation, pituitary apoplexy, tumors, infiltrative disease, and surgical hypophysectomy. Sheehan syndrome is a condition of pituitary failure in which hemorrhagic shock causes vasospasm and subsequent pituitary necrosis in postpartum women.
    2. Anesthetic considerations. Adrenal insufficiency develops over 4 to 14 days after destruction of the pituitary. Perioperative glucocorticoid supplementation may be necessary. Because the half-life of thyroid hormone is 7 to 10 days, symptomatic hypothyroidism does not occur until 3 to 4 weeks after pituitary surgery or apoplexy.

-- To view the remaining sections of this topic, please or purchase a subscription --


Pino, Richard M., editor. "Specific Considerations With Endocrine Disease - Pituitary Disease." Clinical Anesthesia Procedures, 9th ed., Wolters Kluwer, 2019. Anesthesia Central, anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728158/all/Specific_Considerations_with_Endocrine_Disease___Pituitary_Disease.
Specific Considerations with Endocrine Disease - Pituitary Disease. In: Pino RM, ed. Clinical Anesthesia Procedures. 9th ed. Wolters Kluwer; 2019. https://anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728158/all/Specific_Considerations_with_Endocrine_Disease___Pituitary_Disease. Accessed April 24, 2019.
Specific Considerations with Endocrine Disease - Pituitary Disease. (2019). In Pino, R. M. (Ed.), Clinical Anesthesia Procedures. Available from https://anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728158/all/Specific_Considerations_with_Endocrine_Disease___Pituitary_Disease
Specific Considerations With Endocrine Disease - Pituitary Disease [Internet]. In: Pino RM, editors. Clinical Anesthesia Procedures. Wolters Kluwer; 2019. [cited 2019 April 24]. Available from: https://anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728158/all/Specific_Considerations_with_Endocrine_Disease___Pituitary_Disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Specific Considerations with Endocrine Disease - Pituitary Disease ID - 728158 ED - Pino,Richard M, BT - Clinical Anesthesia Procedures UR - https://anesth.unboundmedicine.com/anesthesia/view/ClinicalAnesthesiaProcedures/728158/all/Specific_Considerations_with_Endocrine_Disease___Pituitary_Disease PB - Wolters Kluwer ET - 9 DB - Anesthesia Central DP - Unbound Medicine ER -